Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE The incidence, risk factors, and clinical outcomes of acute kidney injury (staged using the RIFLE classification) associated with intravenous acyclovir administration. 30741619 2018
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE Acute kidney injury (AKI) during the first 7 days was evaluated based on the RIFLE criteria. 29118769 2017
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE Acute kidney injury was defined as the risk, injury, and failure categories, as per the RIFLE (risk, injury, failure, loss, end-stage kidney disease) classification. 23499421 2013
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE We conducted a systematic literature search of studies on AKI according to RIFLE, AKIN, or KDIGO criteria in trauma patients admitted to the ICU (PROSPERO CRD42017060420). 30725141 2019
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE The incidence of acute kidney injury (AKI) was assessed using RIFLE criteria. 31268640 2019
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE Safety was assessed using incidence of acute kidney injury (AKI) based on RIFLE (risk, injury, failure, loss, end-stage renal disease) criteria. 27139010 2017
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE Multivariate analysis identified model for end-stage liver disease score of ≥26 (OR 16.0, p = 0.0012) and post-transplant acute kidney injury (RIFLE criteria I- or F-class; OR 4.87, p = 0.047) as independent risk factors for IFI. 29649828 2019
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE Sepsis patients were divided into no AKI, mild AKI, and severe AKI groups according to RIFLE criteria. 29682165 2018
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE There has been considerable progress over the last decade in the standardization of the acute kidney injury (AKI) definition with the publication of the RIFLE, AKIN, KDIGO and ERBP classification criteria. 30523562 2019
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE Analyses confirmed associations of both RRI thresholds with all consensus AKI definitions (0.74; KDIGO: p = 0.05, AKIN: p = 0.03, RIFLE: p = 0.03, 0.79; KDIGO: p = 0.002, AKIN: p = 0.001, RIFLE: p = 0.004). 31699495 2020
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE Secondary end points included any myocardial ischemia, respiratory and early procedural complications, acute kidney injury (AKI) according to RIFLE criteria (Risk, Injury, Failure, Loss of kidney function, and End-stage renal failure), spinal cord ischemia, a composite of these complications, and postoperative intensive care unit length of stay. 29576405 2018
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE Studies of adult major trauma patients admitted to critical care that applied consensus AKI criteria (risk injury failure loss end stage [RIFLE], AKI network, or kidney disease improving global outcomes) and reported clinical outcomes were assessed (PROSPERO Registration: CRD42017056781). 30358765 2019
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE Three hundred thirty nine patients were included; AKI developed in 141 (41.6%) patients; RISK in 27 (8%) patients; INJURY in 25 (7%); FAILURE in 89 (26%) by the RIFLE criteria. 28143505 2017
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE End points included post-operative death; acute kidney injury (AKI) defined by the RIFLE (Risk, Injury, Failure, Loss of function, End stage renal disease) criteria; and long term follow-up with freedom from chronic renal decline (CRD) and any graft related complications. 31530501 2020
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE This study evaluated the incidence, predictors and prognosis of AKI associated with scrub typhus according to the RIFLE (risk, injury, failure, loss, end-stage kidney disease) criteria. 28298367 2017
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE After suprarenal clamping, 2 retrospective studies used the RIFLE criteria to define the incidence of AKI, and the pooled AKI rate was 36.8%. 27890835 2017
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE AKI was defined and graded using either the modified RIFLE criteria or the Pediatrics RIFLE criteria, while CKD was graded using the KDIGO criteria. 29212494 2017
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE Of 380 children, 53 children (14%) had AKI (met any of the RIFLE criteria). 26752169 2017
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE None of the patients developed acute kidney injury according to RIFLE criteria. 31756180 2019
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE Multivariate logistic regression was used to determine the best predictive models for AKI (RIFLE [renal Risk, Injury, Failure, Loss of renal function and End-stage renal disease] classification), incremental predictive value of minimum cardiopulmonary bypass DO<sub>2</sub>i, and optimal threshold. 31238029 2019
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE AKI was defined according to the RIFLE criteria (risk, injury, failure, loss of kidney function, and end-stage kidney disease): increase by 50% in sCr or reduction of at least 25% of estimated glomerular filtration rate (eGFR) from baseline. 29472806 2018
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE Group I also manifested significantly higher incidence of AKI than group II (62.7% vs. 28.5%, p = 0.005), even when stratified according to RIFLE criteria ('Risk' 33.9% vs. 10.7%; 'Injury' 10.2% vs. 8.9%; 'Failure' 18.6% vs. 8.9%; p = 0.03). 28353411 2017
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE The primary outcome was difference in incidence of AKI evaluated using the RIFLE (risk, injury, failure, loss, and end-stage) criteria. 28760891 2017
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 Biomarker disease BEFREE AKI was determined using the latest definition by AKIN and RIFLE criteria. 30025391 2018
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 Biomarker disease BEFREE The patients with AKI were also classified according to RIFLE as follows: Risk (8.2%), Injury (13.4%), Failure (13.2%), Loss of kidney function (1.3%), and End-stage kidney disease (0.8%). 30581789 2018